October 14, 2019
1 min read
Save

Study to evaluate Cologuard’s real-world impact

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Exact Sciences and the Mayo Clinic are partnering to conduct a study on the real-world, clinical impact of Cologuard on colorectal cancer screening, according to a press release

Researchers aim to enroll more than 150,000 people in the Voyage study, a nationwide, prospective, observational study with at least 7 years follow-up.

“We applaud efforts to gather evidence on the performance and outcomes of colorectal cancer screening,” Paul Limburg, MD, MPH, AGAF, chief medical officer at Exact Sciences and a gastroenterologist at the Mayo Clinic, said in the press release. “This study will be instrumental in further demonstrating the clinical utility of Cologuard, a highly accurate, non-invasive screening option, in our collective effort to reduce the colorectal cancer burden.”

The study will include patients with average risk for CRC who have a valid order for Cologuard and explore how the non-invasive test has affected CRC screening, incidence and mortality rates.

Disclosures: Limburg is employed by Exact Sciences